Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep 12;2012(9):CD004418.
doi: 10.1002/14651858.CD004418.pub4.

Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults

Noa Eliakim-Raz  1 , Eyal Robenshtok, Daphna Shefet, Anat Gafter-Gvili, Liat Vidal, Mical Paul, Leonard Leibovici
Affiliations
Review

Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults

Noa Eliakim-Raz et al. Cochrane Database Syst Rev. .

Abstract

Background: Community-acquired pneumonia (CAP) is caused by various pathogens, traditionally divided into 'typical' and 'atypical'. Initial antibiotic treatment of CAP is usually empirical, customarily covering both typical and atypical pathogens. To date, no sufficient evidence exists to support this broad coverage, while limiting coverage is bound to reduce toxicity, resistance and expense.

Objectives: The main objective was to estimate the mortality and proportion with treatment failure using regimens containing atypical antibiotic coverage compared to those that had typical coverage only. Secondary objectives included the assessment of adverse events.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 3, 2012 which includes the Acute Respiratory Infection Group's Specialized Register, MEDLINE (January 1966 to April week 1, 2012) and EMBASE (January 1980 to April 2012).

Selection criteria: Randomized controlled trials (RCTs) of adult patients hospitalized due to CAP, comparing antibiotic regimens with atypical coverage (quinolones, macrolides, tetracyclines, chloramphenicol, streptogramins or ketolides) to a regimen without atypical antibiotic coverage.

Data collection and analysis: Two review authors independently assessed the risk of bias and extracted data from included trials. We estimated risk ratios (RRs) with 95% confidence intervals (CIs). We assessed heterogeneity using a Chi(2) test.

Main results: We included 28 trials, encompassing 5939 randomized patients. The atypical antibiotic was administered as monotherapy in all but three studies. Only one study assessed a beta-lactam combined with a macrolide compared to the same beta-lactam. There was no difference in mortality between the atypical arm and the non-atypical arm (RR 1.14; 95% CI 0.84 to 1.55), RR < 1 favors the atypical arm. The atypical arm showed an insignificant trend toward clinical success and a significant advantage to bacteriological eradication, which disappeared when evaluating methodologically high quality studies alone. Clinical success for the atypical arm was significantly higher for Legionella pneumophilae (L. pneumophilae) and non-significantly lower for pneumococcal pneumonia. There was no significant difference between the groups in the frequency of (total) adverse events, or those requiring discontinuation of treatment. However, gastrointestinal events were less common in the atypical arm (RR 0.70; 95% CI 0.53 to 0.92). Although the trials assessed different antibiotics, no significant heterogeneity was detected in the analyses.

Authors' conclusions: No benefit of survival or clinical efficacy was shown with empirical atypical coverage in hospitalized patients with CAP. This conclusion relates mostly to the comparison of quinolone monotherapy to beta-lactams. Further trials, comparing beta-lactam monotherapy to the same combined with a macrolide, should be performed.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1
1
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
3
3
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Aubier 1998 {published data only}
    1. Aubier M, Verster R, Regamey C, Geslin P, Vercken JB, Sparfloxacin European Study Group. Once‐daily sparfloxacin versus high‐dosage amoxicillin in the treatment of community‐acquired, suspected pneumococcal pneumonia in adults. Clinical Infectious Diseases 1998;26(6):1312‐20. - PubMed
Bohte 1995 {published data only}
    1. Bohte R, van't Wout JW, Lobatto S, Blusse van Oud Alblas A, Boekhout M, Nauta EH, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community‐acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1995;14(3):182‐7. - PubMed
Carbon 1992 {published data only}
    1. Carbon C, Lephonte P, Petitpretz P, Chauvin JP, Hazebroucq J. Efficacy and safety of temafloxacin versus those of amoxicillin in hospitalized adults with community‐acquired pneumonia. Antimicrobial Agents and Chemotherapy 1992;36(4):833‐9. - PMC - PubMed
Chuard 1989 {published data only}
    1. Chuard C, Regamey C. Effect and tolerance of ofloxacin in bronchopulmonary infections in comparison with amoxicillin. Schweizerische Medizinische Wochenschrift 1989;119(52):1913‐6. - PubMed
Feldman 2001 {published data only}
    1. Feldman C, White H, O'Grady J, Flitcroft A, Briggs A, Richards G. An open, randomised, multi‐centre study comparing the safety and efficacy of sitafloxacin and imipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. International Journal of Antimicrobial Agents 2001;17(3):177‐88. - PubMed
Fourrier 1986 {published data only}
    1. Fourrier F, Chopin C, Lestavel P, Savage C. Initial antibiotherapy in severe bacterial bronchopneumopathies. Randomized study of a new quinolone: pefloxacin. La Presse Medicale 1986;15(26):1240. - PubMed
Genne 1997 {published data only}
    1. Genné D, Siegrist HH, Humair L, Janin‐Jaquat B, Torrenté A. Clarithromycin versus amoxicillin‐clavulanic acid in the treatment of community‐acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1997;16(11):783‐8. - PubMed
Gleadhill 1986 {published data only}
    1. Gleadhill IC, Ferguson WP, Lowry RC. Efficacy and safety of ciprofloxacin in patients with respiratory infections in comparison with amoxycillin. Journal of Antimicrobial Chemotherapy 1986;18(Supp D):133‐8. - PubMed
Hatipoglu 2010 {unpublished data only}
    1. Hatipoglu ON, Uysal S, Altiay G, Sut N, Tabakoglu E. The effect of addition of macrolide to a beta‐lactam antibiotic on treatment success in patients with moderately severe community acquired pneumonia (Abstract). Proceedings of the European Respiratory Society Annual Congress; 2010 September 18‐22; Barcelona, Spain. 2010.
Hirata‐Dulas 1991 {published data only}
    1. Hirata‐Dulas CA, Stein DJ, Guay DR, Gruninger RP, Peterson PK. A randomized study of ciprofloxacin versus ceftriaxone in the treatment of nursing home‐acquired lower respiratory tract infections. Journal of the American Geriatrics Society 1991;39(10):979‐85. - PubMed
Hong‐yun 2007 {published data only}
    1. Hong‐yun L, Chao Q, Qian L, Qun F. Observation of the therapeutic effects of gatifloxacin on community acquired pneumonia. Chinese Journal of Antibiotics 2007, (5).
Kalbermatter 2000 {published data only}
    1. Kalbermatter V, Bagilet D, Diab M, Javkin E. Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community‐acquired pneumonia that requires hospitalization. Medicina Clinica 2000;115(15):561‐3. - PubMed
Khan 1989 {published data only}
    1. Khan FA, Basir R. Sequential intravenous‐oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. Chest 1989;96(3):453‐6. - PubMed
Kobayashi 1984 {published data only}
    1. Kobayashi H, Takamura K, Kono K, Onodera S, Sasaki N, Nagahama F, et al. Comparison of DL‐8280 and amoxicillin in the treatment of respiratory tract infections. Kansenshogaku Zasshi 1984;58(6):525‐55. - PubMed
Kohno 2011 {published data only}
    1. Kohno S, Watanabe A, Aoki N, Niki Y, Kadota J, Fujita J, et al. Clinical phase III comparative study of intravenous levofloxacin and ceftriaxone in community‐acquired pneumonia treatment. Japanese Journal of Chemotherapy 2011;59:32‐45.
Lephonte 2004 {published data only}
    1. Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community‐acquired pneumonia of suspected pneumococcal origin. Respiratory Medicine 2004;98(8):708‐20. - PubMed
Lode 1995 {published data only}
    1. Lode H, Garau J, Grassi C, Hosie J, Huchon G, Legakis N, et al. Treatment of community‐acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin‐clavulanic acid and erythromycin. European Respiratory Journal 1995;8(12):1999‐2007. - PubMed
Miki 1984 {published data only}
    1. Miki F, Saito A, Tomizawa M, Nakayama I, Takebe K, Takashima T, et al. Comparative study of the effectiveness of enoxacin and amoxicillin in bacterial pneumonia by a double blind method. Kansenshogaku Zasshi 1984;58(10):1083‐113. - PubMed
Norrby 1998 {published data only}
    1. Norrby SR, Petermann W, Willcox PA, Vetter N, Salewski E. A comparative study of levofloxacin and ceftriaxone in the treatment of hospitalized patients with pneumonia. Scandinavian Journal of Infectious Diseases 1998;30(4):397‐404. - PubMed
Peterson 1988 {published data only}
    1. Peterson PK, Stein D, Guay DR, Logan G, Obaid S, Gruninger R, et al. Prospective study of lower respiratory tract infections in an extended‐care nursing home program: potential role of oral ciprofloxacin. American Journal of Medicine 1988;85(2):164‐71. - PubMed
Petitpretz 2001 {published data only}
    1. Jardim JR, Rico G, Roza C, Obispo E, Urueta J, Wolff M, et al. A comparison of moxifloxacin and amoxicillin in the treatment of community‐acquired pneumonia in Latin America: results of a multicenter clinical trial. Archives de Bronchoneumologia 2003;39(9):387‐93. - PubMed
    1. Petitpretz P, Arvis P, Marel M, Moita J, Urueta J, CAP5 Moxifloxacin Study Group. Oral moxifloxacin vs high‐dosage amoxicillin in the treatment of mild‐to‐moderate, community‐acquired, suspected pneumococcal pneumonia in adults. Chest 2001;119(1):185‐95. - PubMed
Rizzato 1997 {published data only}
    1. Allegra L, Berni F, Boisisio E, Clini V, Dal Negro R, Damato S, et al. Efficacy of the teicoplanin‐ciprofloxacin combination in high risk community acquired pneumonia: Comparison to ceftriaxone in a multicenter study. Internista 1995;31:39‐43.
    1. Montemurro L, Rizzato G, Multicenter Study Group. The teicoplanin‐ciprofloxacin combination versus ceftriaxone in community acquired pneumonia of elderly and patients with underlying diseases. European Respiratory Journal 1993;7(Supp 18):170.
    1. Rizzato G, Allegra L: Multicentre Italian Study Group (co‐ordinated by Centro Thorax). Efficacy and tolerability of teicoplanin‐ciprofloxacin combination in severe community‐acquired pneumonia. Comparison with ceftriaxone in a multicentre Italian study. Clinical Drug Investigation 1997;14(5):337‐45.
Romanelli 2002 {published data only}
    1. Romanelli G, Cravarezza P, Pozzi A, Franchino L, Ravizzola G, Zulli R, et al. Carbapenems in the treatment of severe community‐acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy. Journal of Chemotherapy 2002;14(6):609‐17. - PubMed
Tremolieres 1998 {published data only}
    1. Tremolieres F, Kock F, Pluck N, Daniel R. Trovafloxacin versus high‐dose amoxicillin (1g three times daily) in the treatment of community‐acquired bacterial pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1998;17(6):447‐53. - PubMed
Tremolieres 2005 {published data only}
    1. Tremolieres F, Mayaud C, Mouton Y, Weber P, Dellatolas F, Caulin E. Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults. Pathologie‐biologie (Paris) 2005;53(8‐9):503‐10. - PubMed
Vanderdonckt 1990 {published data only}
    1. Vanderdonckt J. Comparison of pefloxacin with ceftazidime in severe bronchopulmonary infections. Journal of Antimicrobial Chemotherapy 1990;26(Suppl B):111‐6. - PubMed
Vogel 1991 {published data only}
    1. Vogel F, Lode H. The use of oral temafloxacin compared with a parenteral cephalosporin in hospitalized patients with pneumonia. Journal of Antimicrobial Chemotherapy 1991;28(Supp C):81‐6. - PubMed
Zeluff 1988 {published data only}
    1. Zeluff BJ, Lowe P, Koorhof HJ, Gentry LO. Evaluation of roxithromycin (RU‐965) versus cephradine in pneumococcal pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1988;7(1):69‐71. - PubMed

References to studies excluded from this review

Ailani 1999 {published data only}
    1. Ailani RK, Agastya G, Ailani RK, Mukunda BN, Shekar R. Doxycycline is a cost‐effective therapy for hospitalized patients with community‐acquired pneumonia. Archives of Internal Medicine 1999;159(3):266‐70. - PubMed
Aubier 1996 {published data only}
    1. Aubier M, Lode H, Gialdroni‐Grassi G, Huchon G, Hosie J, Legakis N, et al. Sparfloxacin for the treatment of community‐acquired pneumonia: a pooled data analysis of two studies. Journal of Antimicrobial Chemotherapy 1996;37(Suppl A):73‐82. - PubMed
Chokshi 2007 {published data only}
    1. Chokshi R, Restrepo MI, Weeratunge N, Frei CR, Anzueto A, Mortensen EM. Monotherapy versus combination antibiotic therapy for patients with bacteremic Streptococcus pneumoniae community‐acquired pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 2007;26(7):447‐51. - PubMed
Donowitz 1997 {published data only}
    1. Donowitz GR, Brandon ML, Salisbury JP, Harman CP, Tipping DM, Urick AE, et al. Sparfloxacin versus cefaclor in the treatment of patients with community‐acquired pneumonia: a randomized, double‐masked, comparative, multicenter study. Clinical Therapeutics 1997;19(5):936‐53. - PubMed
Fass 1989 {published data only}
    1. Fass RJ, Plouffe JF, Russell JA. IV/oral ciprofloxacin vs ceftazidime in the treatment of serious infections. American Journal of Medicine 1989;87(5A):164‐8. - PubMed
File 1997 {published data only}
    1. File TM, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community‐acquired pneumonia. Antimicrobial Agents and Chemotherapy 1997;41(9):1965‐72. - PMC - PubMed
Fink 1994 {published data only}
    1. Fink MP, Snydman DR, Niederman MS, Leeper KV Jr, Johnson RH, Heard SO, et al. The Severe Pneumonia Study Group. Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double‐blind trial comparing intravenous ciprofloxacin with imipenem‐cilastatin. Antimicrobial Agents and Chemotherapy 1994;38(3):547‐57. - PMC - PubMed
Fong 1995 {published data only}
    1. Fong IW, Laforge J, Dubois J, Small D, Grossman R, Zakhari R, The Canadian Bronchitis Study Group. Clarithromycin versus cefaclor in lower respiratory tract infections. Clinical and Investigative Medicine. Médecine Clinique et Experimentale 1995;18(2):131‐8. - PubMed
Geijo Martinez 2002 {published data only}
    1. Geijo Martinez MP, Diaz de Tuesta, Chow‐Quan AM, Herranz CR, Gomez Criado C, Dimas Nunez JF, et al. Levofloxacin versus beta‐lactamic therapy in community acquired pneumonia that requires hospitalisation [Levofloxacino frente a betalactamicos en el tratamiento de la neumonia adquirida en la comunidad con ingreso hospitalario]. Anales de Medicina Interna 2002;19(12):609‐11. - PubMed
Hagberg 2002 {published data only}
    1. Hagberg L, Torres A, Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once‐daily telithromycin compared with high‐dose amoxicillin for treatment of community‐acquired pneumonia. Infection 2002;30(6):378‐86. - PubMed
Hoepelman 1993 {published data only}
    1. Hoepelman AI, Sips AP, Helmond JL, Barneveld PW, Neve AJ, Zwinkels M, et al. A single‐blind comparison of three‐day azithromycin and ten‐day co‐amoxiclav treatment of acute lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1993;31(Suppl E):147‐52. - PubMed
Katz 2004 {published data only}
    1. Katz E, Larsen LS, Fogarty CM, Hamed K, Song J, Choudhri S. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community‐acquired pneumonia in patients requiring initial i.v. therapy. Journal of Emergency Medicine 2004;27(4):395‐405. - PubMed
Khajotia 1990 {published data only}
    1. Khajotia R, Drlicek M, Vetter N. A comparative study of ofloxacin and amoxycillin/clavulanate in hospitalized patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 1990;26(Suppl D):83‐91. - PubMed
Kinasewitz 1991 {published data only}
    1. Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. European Journal of Clinical Microbiology and Infectious Diseases 1991;10(10):872‐7. - PubMed
Krumpe 1999 {published data only}
    1. Krumpe PE, Cohn S, Garreltes J, Ramirez J, Coulter H, Haverstock D, et al. Ciprofloxacin Study Group. Intravenous and oral mono‐ or combination‐therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Journal of Antimicrobial Chemotherapy 1999;43(Supp A):117‐28. - PubMed
Kuzman 2005 {published data only}
    1. Kuzman I, Dakovic‐Rode O, Oremus M, Banaszak AM. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community‐acquired pneumonia: an international, randomized, open‐label study. Journal of Chemotherapy 2005;17(6):636‐42. - PubMed
Leophonte 1999 {published data only}
    1. Leophonte P, Veyssier P. Levofloxacin in the treatment of community‐acquired pneumococcal pneumonia. La Presse Medicale 1999;28(36):1975‐9. - PubMed
Levine 1989 {published data only}
    1. Levine D, McNeil P, Lerner SA. Randomized, double‐blind comparative study of intravenous ciprofloxacin versus ceftazidime in the treatment of serious infections. American Journal of Medicine 1989;87(5A):160‐3. - PubMed
Lode 1987 {published data only}
    1. Lode H, Wiley R, Hoffken G, Wagner J, Borner K, Lode H, et al. Prospective randomized controlled study of ciprofloxacin versus imipenem‐cilastatin in severe clinical infections. Antimicrobial Agents and Chemotherapy 1987;31(10):1491‐6. - PMC - PubMed
Lode 1990 {published data only}
    1. Lode H, Wiley E, Olschewski P, Sievers H, Wintermantel M, Baetz R, et al. Prospective randomized clinical trials of new quinolones versus beta‐lactam antibiotics in lower respiratory tract infections. Scandinavian Journal of Infectious Diseases 1990;68(Suppl):50‐5. - PubMed
Lode 1998 {published data only}
    1. Lode H, Aubier M, Portier H, Ortquist A, Sparfloxacin Study Group. Sparfloxacin as alternative treatment to standard therapy for community‐acquired bacteremic pneumococcal pneumonia. Clinical Microbiology and Infection 1998;4(3):135‐43. - PubMed
Lode 2004 {published data only}
    1. Lode H, Magyar P, Muir JF, Loos U, Kleutgens K, International Gatifloxacin Study Group. Once‐daily oral gatifloxacin vs three‐times‐daily co‐amoxiclav in the treatment of patients with community‐acquired pneumonia. Clinical Microbiology and Infection 2004;10(6):512‐20. - PubMed
Mendoca 2004 {published data only}
    1. Mendonca JS, Yamaguti A, Correa JC, Badaro R. Gatifloxacin in the treatment of community‐acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia. Brazilian Journal of Infectious Diseases 2004;8(1):90‐100. - PubMed
Mouton 1991 {published data only}
    1. Mouton Y, Beuscart C, Leroy O, Ajana F, Charrel J, Groupe Multicentrique. Evaluation of ciprofloxacin versus amoxicillin + clavulanic acid or erythromycin for the empiric treatment of community‐acquired pneumonia. Pathologie‐Biologie 1991;39(1):34‐7. - PubMed
O'Doherty 1997 {published data only}
    1. O'Doherty BO, Dutchman DA, Pettit R, Maroli A. Randomized, double blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community‐acquired pneumonia. Journal of Antimicrobial Chemotherapy 1997;40(Supp A):73‐81. - PubMed
Ott 2008 {published data only}
    1. Ott SR, Allewelt M, Lorenz J, Reimnitz P, Lode H. Moxifloxacin vs ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008;36(1):23‐30. - PubMed
Peacock 1987 {published data only}
    1. Peacock J Jr, Pegram SP, Weber SF, Leone PA. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. American Journal of Medicine 1989;87(5A):185S‐90S. - PubMed
Plouffe 1996 {published data only}
    1. Plouffe JF, Herbert MT, File TM Jr, Baird I, Parsons JN, Kahn JB, et al. Ofloxacin versus standard therapy in treatment of community‐acquired pneumonia requiring hospitalization. Antimicrobial Agents and Chemotherapy 1996;40(5):1175‐9. - PMC - PubMed
Rahav 2004 {published data only}
    1. Rahav G, Fidel J, Gibor Y, Shapiro M. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. International Journal of Antimicrobial Agents 2004;24(2):181‐4. - PubMed
Siami 1995 {published data only}
    1. Siami GA, Wilkins WT, Bess DT, Christman JW. Comparison of ciprofloxacin with imipenem in the treatment of severe pneumonia in hospitalised geriatric patients. Drugs 1995;49(Supp 2):436‐8. - PubMed
Sifuentes 1989 {published data only}
    1. Sifuentes‐Osornio J, Macias A, Amieva RI, Ramos A, Ruiz‐Palacios GM. Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third‐party blinding. American Journal of Medicine 1989;87(5A):202S‐5S. - PubMed
Snydman 1995 {published data only}
    1. Snydman D, Fink F, Niederman M, Reinhart H. Treatment of severe pneumonia in hospitalised patients. Results of a multicentre trial comparing i.v. ciprofloxacin with imipenem/cilastatin. Drugs 1995;49(Supp 2):439‐41. - PubMed
Stocks 1989 {published data only}
    1. Stocks JM, Wallace RJ Jr, Griffith DE, Garcia JG, Kohler RB. Ofloxacin in community‐acquired lower respiratory infections. A comparison with amoxicillin or erythromycin. American Journal of Medicine 1989;87(6C):52‐6. - PubMed
Sujata 2008 {published data only}
    1. Bhavnani SM, Ambrose PG. Cost‐effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community‐acquired pneumonia. Diagnostic Microbiology and Infectious Disease 2008;60(1):59‐64. - PubMed
Torres 2003 {published data only}
    1. Torres A, Muir JF, Corris P, Kubin R, Duprat‐Lomon I, Sagnier PP, et al. Effectiveness of oral moxifloxacin in standard first‐line therapy in community‐acquired pneumonia. European Respiratory Journal 2003;21(1):135‐43. - PubMed
Trenholme 1989 {published data only}
    1. Trenholme GM, Schmitt BA, Spear J, Gvazdinskas LC. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lower respiratory tract infections. American Journal of Medicine 1989;87(Supp 5A):116S‐8S. - PubMed
Welte 2005 {published data only}
    1. Welte T, Petermann W, Schurmann D, Bauer TT, Reimnitz P. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community‐acquired pneumonia who received initial parenteral therapy. Clinical Infectious Diseases 2005;41(12):1697‐705. - PubMed
Wollschlager 1987 {published data only}
    1. Wollschlager CM, Raoof S, Khan FA, Guarneri JJ, LaBombardi V, Afzal Q. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections. American Journal of Medicine 1987;82(4A):164‐8. - PubMed

Additional references

BTS 2001
    1. British Thoracic Society. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001;56(Suppl 4:IV):1‐64. - PMC - PubMed
Donowitz 2000
    1. Donowitz G, Mandell G. Acute Pneumonia. In: Mandell GL, Bennet JE, Dolin R editor(s). Principles and Practice of Infectious Diseases. 5th Edition. Vol. 1, Philadelphia: Churchill Livingstone, 2000:717‐43.
FDA 2009
    1. FDA. Guidance for industry. Patient‐reported outcome measures: use in medical product development to support labeling claims. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid... (accessed May 2010) (accessed May 2010). - PMC - PubMed
Fine 1997
    1. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low‐risk patients with community‐acquired pneumonia. New England Journal of Medicine 1997;336(4):243‐50. - PubMed
Hedlund 2005
    1. Hedlund J, Stralin K, Ortqvist A, Holmberg H. Swedish guidelines for the management of community‐acquired pneumonia in immunocompetent adults. Scandinavian Journal of Infectious Diseases 2005;37:791‐805. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane‐handbook.org 2011.
Iezzoni 1988
    1. Iezzoni LI, Moskowitz MA. A clinical assessment of MedisGroups. JAMA 1988;260(21):3159‐63. - PubMed
Johansen 2000
    1. Johansen HK, Jensen TG, Dessau RB, Lundgren B, Frimodt‐Moller N. Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo. Journal of Antimicrobial Chemotherapy 2000;46:973‐80. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Levison 2001
    1. Levison M. Pneumonia, including necrotizing pulmonary infections (lung abscess). In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL editor(s). Harrison's Principles of Internal Medicine. 15th Edition. Vol. 2, New York: McGraw‐Hill, 2001:1475‐85.
Lim 2003
    1. Lim WS, Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58(5):377‐82. - PMC - PubMed
Lim 2009
    1. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2009;64(Suppl 3):1‐55. - PubMed
Malhotra‐Kumar 2007
    1. Malhotra‐Kumar S, Lammens C, Coenen S, Herck K, Goossens H. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide‐resistant streptococci in healthy volunteers: a randomised, double‐blind, placebo‐controlled study. Lancet 2007;369(9560):482‐90. - PubMed
Mandell 2000
    1. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH, The Canadian Community‐Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community‐acquired pneumonia: an evidence‐based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clinical Infectious Diseases 2000;31:383‐421. - PubMed
Mandell 2007
    1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community‐acquired pneumonia in adults. Clinical Infectious Diseases 2007;44(Suppl 2):27‐72. - PMC - PubMed
Mills 2005
    1. Mills DG, Oehley MR, Arrol B. Effectiveness of beta‐lactam antibiotics compared with antibiotics active against atypical pathogens in non‐severe community acquired pneumonia: meta‐analysis. BMJ 2005;330(7489):456. - PMC - PubMed
Niederman 2001
    1. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. American Thoracic Society. Guidelines for the management of adults with community‐acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. American Journal of Respiratory and Critical Care Medicine 2001;163(7):1730‐54. - PubMed
Oosterheert 2003
    1. Oosterheert JJ, Bonten MJM, Hak E, Schneider MM, Hoepelman IM. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community‐acquired pneumonia? A systematic review. Journal of Antimicrobial Chemotherapy 2003;52(4):555‐63. - PubMed
Paul 2007
    1. Paul M, Nielsen AD, Gafter‐Gvili A, Tacconelli E, Andreassen S, Almanasreh N, et al. The need for macrolides in hospitalised community‐acquired pneumonia: propensity analysis. European Respiratory Journal 2007 May 30 [Epub ahead of print]. - PubMed
Ross 2007
    1. Ross DB. The FDA and the case of Ketek. New England Journal of Medicine 2007;356(16):1601‐4. - PubMed
Soreth 2007
    1. Soreth J, Cox E, Kweder S, Jenkins J, Galson S. Ketek ‐ the FDA perspective. New England Journal of Medicine 2007;356(16):1675‐6. - PubMed
Woodhead 2005
    1. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. European Respiratory Journal 2005;26:1138‐80. - PubMed
Woodhead 2011
    1. Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. Clinical Microbiology infections 2011;17(6):1‐24. - PubMed

References to other published versions of this review

Robenshtok 2008
    1. Robenshtok E, Shefet D, Gafter‐Gvili A, Paul M, Vidal L, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community‐acquired pneumonia in hospitalized adults. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004418.pub3] - DOI - PubMed
Shefet 2005
    1. Shefet D, Robenshtok E, Paul M, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community‐acquired pneumonia in hospitalized adults. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD004418.pub3] - DOI - PubMed

MeSH terms

Substances